Clopidogrel Monotherapy Appropriateness Checker Tool
Clinical assessment
Review timing, bleeding and ischemic events, anticoagulation, and clopidogrel response before considering a regimen.
Clinical context
Dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor is the default for at least 12 months after ACS in patients who are not at high bleeding risk. Selected patients after PCI may be considered for an abbreviated course to reduce bleeding risk, but the best single-antiplatelet strategy depends on the clinical setting.
Important distinctions
- Clopidogrel monotherapy: clopidogrel is the only antiplatelet agent; this does not mean anticoagulation is being provided.
- Clopidogrel plus oral anticoagulation: this is a combined antithrombotic regimen for patients with a separate indication for anticoagulation.
- De-escalation: switching from ticagrelor or prasugrel to clopidogrel while continuing aspirin is not the same as stopping aspirin and using clopidogrel alone.
- High bleeding risk: may support considering abbreviated therapy in selected patients, but does not automatically establish clopidogrel as the preferred single agent.
Limitations
This rule-based tool does not calculate a validated ischemic or bleeding score and does not replace review of PCI details, stent-thrombosis risk, ACS presentation, adherence, contraindications, drug interactions, or the reason for oral anticoagulation.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.